SEALS | A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c.

Topic / Pathology

  • ACT4ALS-MND
  • Phase 2
  • ALS

Objectives

To assess the effect of NX210c on blood neurofilament light chain (NfL) or on a blood and cerebrospinal fluid (CSF) biomarker of BBB integrity at 6-week follow-up. 

Learn more about : https://clinicaltrials.gov/study/NCT06365216 

Sponsor

AXOLTIS Pharma

Investigator

National coordinator : Dr Emilien Bernard

Partnership(s) with patients association(s)

Scientific publication(s)

Status

Preliminary research results available

Participating centers

Share

Updated on 16 September 2026